Psychopharmacology

A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.

Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Experts urge caution prescribing GLP-1s for patients with eating disorders, highlighting motivation checks, psychoeducation, and team-based care.

GLP-1 weight-loss drugs may aid binge eating, but clinicians must screen for eating disorders and monitor patients with multidisciplinary care.

Learn how to launch TMS or Spravato services—costs, billing, REMS logistics, training, and what’s next in interventional psychiatry.

After 2 antidepressant trials, TMS or esketamine offers faster relief and durable remission—see why clinicians switch sooner.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Potential anti-anxiety agent SNTX-2643 blunted the brain's stress response for 24 hours, with no dissociative or abuse-related effects.

Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.

Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.

Brenipatide being investigated for alcohol use disorder, while exploring relapse prevention in recurrent depression and other psychiatric conditions.

Phase 1 brenipatide shows week-long exposure and tolerable GI effects, fueling studies in alcohol and other substance use disorders.

New phase 3 data test PP-01 to ease cannabis withdrawal, pairing medication with behavioral therapy for moderate-to-severe cannabis use disorder.

Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.

A fast-tracked once-daily pill aims to ease cannabis withdrawal by restoring CB1 signaling and reward-pathway balance as phase 3 enrollment surges.

Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.

FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.

Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.

Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.

Clinicians learn how to assess and treat sexual dysfunction in depression, menopause, and psych meds—plus drug options that preserve desire and arousal.

Review the developments in GLP-1s in 2026.

Learn how gene variants shape CYP450 metabolism, receptors, and transporters—explaining intermediate phenotypes that influence psychiatric medication response.